{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:36Z","timestamp":1789958856671,"version":"4.0.1"},"reference-count":57,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST110\u20102320\u2010B038\u2010064\u2010MY3"],"award-info":[{"award-number":["MOST110\u20102320\u2010B038\u2010064\u2010MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST111\u20102314\u2010B038\u2010120\u2010MY3"],"award-info":[{"award-number":["MOST111\u20102314\u2010B038\u2010120\u2010MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST111\u20102320\u2010B038\u2010012"],"award-info":[{"award-number":["MOST111\u20102320\u2010B038\u2010012"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST111\u20102327\u2010B006\u2010005"],"award-info":[{"award-number":["MOST111\u20102327\u2010B006\u2010005"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,9]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>The efficacy of CD22 or CD19 chimeric antigen receptor T (CAR\u2010T) cells in the management of acute lymphoblastic leukemia (ALL) and non\u2010Hodgkin lymphoma (NHL) was observed. Because antigen loss and lack of CAR\u2010T\u2010cell persistence are the leading causes of progressive disease following single\u2010antigen targeting, we evaluated CD22\/CD19 dual\u2010targeting CAR\u2010T\u2010cell therapy efficacy and safety in relapsed\/refractory B\u2010cell malignancies.<\/jats:p><\/jats:sec>Methods<\/jats:title>The Web of Science, PubMed, Cochrane, and Embase databases were searched until July 2022. Patients confirmed with any relapsed\/refractory B\u2010cell hematological malignancies were included regardless of age, gender, or ethnicity, receiving CD22 and CD19\u2010dual\u2010targeting CAR\u2010T\u2010cell therapy. The studies conducted on patients with coexisting other cancer were excluded. We used random\u2010effect models to explore the outcome, and heterogeneity was investigated by subgroup analysis.<\/jats:p><\/jats:sec>Results<\/jats:title>Fourteen studies (405 patients) were included. The pooled overall response (OR) and complete remission (CR) were 97% and 93%, respectively, for ALL patients. The 1\u2010year proportions of overall survival (OS) and progression\u2010free survival (PFS) were 70% and 49%, respectively. For NHL, OR occurred in 85% of patients, and 57% experienced CR. The results illustrated that the 1\u2010year OS and 1\u2010year PFS were 77% and 65%, respectively. The subgroup analysis showed that the dual\u2010targeting modality achieved higher CR in the following cases: coadministration of CD22\/CD19\u2010CAR\u2010T\u2009cells and third\u2010generation CAR\u2010T cells combined with ASCT and BEAM pretreatment. The ALL and NHL groups seemed similar in treatment\u2010related toxicity: all grade cytokine release syndrome (CRS), severe CRS, and neurotoxicity occurred in 86%, 7%, and 12% of patients, respectively.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Our meta\u2010analysis demonstrated that the CD22\/CD19 dual\u2010targeting CAR\u2010T\u2010cell strategy has high efficiency with tolerable adverse effects in B\u2010cell malignancies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6497","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:23:41Z","timestamp":1693905821000},"page":"18767-18785","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness and safety of CD22<\/scp> and CD19<\/scp> dual\u2010targeting chimeric antigen receptor T\u2010cell therapy in patients with relapsed or refractory B\u2010cell malignancies: A meta\u2010analysis"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-574X","authenticated-orcid":false,"given":"Thi Thuy","family":"Nguyen","sequence":"first","affiliation":[{"name":"International Ph.D. Program in Medicine, College of Medicine Taipei Medical University Taipei Taiwan"},{"name":"Department of Oncology Hue University of Medicine and Pharmacy, Hue University Hue Vietnam"},{"name":"Department of Microbiology and Immunology, School of Medicine, College of Medicine Taipei Medical University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-6061","authenticated-orcid":false,"given":"Nguyen","family":"Thanh\u00a0Nhu","sequence":"additional","affiliation":[{"name":"International Ph.D. Program in Medicine, College of Medicine Taipei Medical University Taipei Taiwan"},{"name":"Faculty of Medicine Can Tho University of Medicine and Pharmacy Can Tho Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2161-4362","authenticated-orcid":false,"given":"Chia\u2010Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Respiratory Therapy, College of Medicine Taipei Medical University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4396-6086","authenticated-orcid":false,"given":"Chiou\u2010Feng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, School of Medicine, College of Medicine Taipei Medical University Taipei Taiwan"},{"name":"Core Laboratory of Immune Monitoring, Office of Research & Development Taipei Medical University Taipei Taiwan"},{"name":"Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30823-X"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0488-7"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox182"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00146"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.03.020"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164879"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000525"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0758"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0062"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4817-4"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-580027"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"e_1_2_10_29_1","unstructured":"Health UDo text HSJBtcNational Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 403;2010.2019(5):6\u201314."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"e_1_2_10_31_1","first-page":"12","article-title":"Prognostic value of radiomic features of 18F\u2010FDG PET\/CT in patients with B\u2010cell lymphoma treated with CD19\/CD22 dual\u2010targeted chimeric antigen receptor T cells","volume":"12","author":"Zhou Y","year":"2022","journal-title":"Frontiers Oncology"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.08.012"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01497-1"},{"issue":"1","key":"e_1_2_10_35_1","first-page":"1","article-title":"Bispecific CAR\u2010T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai H","year":"2020","journal-title":"J Hematol Oncol"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3863"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00270-5"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00924-0"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26160"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000017"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0675"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.01.008"},{"key":"e_1_2_10_43_1","first-page":"11","article-title":"A prospective investigation of bispecific CD19\/22 CAR T cell therapy in patients with relapsed or refractory B cell non\u2010Hodgkin lymphoma","volume":"11","author":"Zhang Y","year":"2021","journal-title":"Front Oncol"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00523-2"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2020.05.005"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130983"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.010"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003482"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30277-5"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000568"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.07.014"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018883421"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0075"},{"issue":"1","key":"e_1_2_10_56_1","first-page":"578","article-title":"Long\u2010term follow\u2010up ZUMA\u20101: a pivotal trial of axicabtagene ciloleucel (Axi\u2010Cel; KTE\u2010C19) in patients with refractory aggressive non\u2010Hodgkin lymphoma (NHL)","volume":"130","author":"Neelapu SS","year":"2017","journal-title":"Blood"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000952"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.5868"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T05:37:04Z","timestamp":1705642624000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":57,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/cam4.6497"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6497","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2022-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}